Welcome to Dyne Medical Central publications portal

At Dyne Therapeutics, we are focused on delivering functional improvement for people living with genetically driven neuromuscular diseases. On this publications portal, you will find the latest congress presentations and peer-reviewed publications from Dyne.

The FORCE™ platform, zeleciment-basivarsen (z-basivarsen, also known as DYNE-101), zeleciment-rostudirsen (z-rostudirsen, also known as DYNE-251), DYNE-302, and DYNE-401 are investigational or otherwise in development and have not been approved as safe or effective by the US FDA, EMA or any other regulatory authority.